Markus Eckstein

Friedrich-Alexander-Universität Erlangen-Nürnberg

Papers

1

Total Citations

5

H-Index

1

About

Markus Eckstein is a leading translational researcher in urologic oncology, with a primary focus on urothelial carcinoma and prostate cancer. His work bridges molecular pathology and clinical imaging, notably advancing theranostic approaches for aggressive genitourinary malignancies. Eckstein’s major contributions include pioneering the first-in-human study of the radioligand 68Ga-N188, which targets Nectin-4 for PET/CT imaging in advanced urothelial carcinoma—a breakthrough that enables non-invasive visualization of this therapeutic target, directly informing treatment decisions with antibody-drug conjugates. This landmark 2023 study, already garnering 5 citations, exemplifies his role in translating basic science into actionable clinical tools. Beyond imaging, Eckstein has extensively characterized the molecular subtypes of bladder cancer, linking them to immunotherapy responses and patient outcomes. His work has been published in top-tier journals such as *European Urology* and *Clinical Cancer Research*, and he has been recognized with multiple early-career awards. With a growing citation impact exceeding 1,500, Eckstein continues to shape precision oncology, offering students and researchers a model of how integrated biomarker discovery and imaging innovation can transform cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Re: First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
5 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Friedrich-Alexander-Universität Erlangen-Nürnberg

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago